Pharma Mar Statistics
Total Valuation
Pharma Mar has a market cap or net worth of 1.44 billion. The enterprise value is 1.33 billion.
| Market Cap | 1.44B |
| Enterprise Value | 1.33B |
Important Dates
The last earnings date was Friday, April 25, 2025.
| Earnings Date | Apr 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 12.74M |
Valuation Ratios
The trailing PE ratio is 66.83.
| PE Ratio | 66.83 |
| Forward PE | n/a |
| PS Ratio | 7.56 |
| PB Ratio | 6.73 |
| P/TBV Ratio | 6.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 84.71, with an EV/FCF ratio of -69.40.
| EV / Earnings | 62.12 |
| EV / Sales | 6.67 |
| EV / EBITDA | 84.71 |
| EV / EBIT | 152.69 |
| EV / FCF | -69.40 |
Financial Position
The company has a current ratio of 2.97, with a Debt / Equity ratio of 0.26.
| Current Ratio | 2.97 |
| Quick Ratio | 2.23 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | 3.75 |
| Debt / FCF | -2.92 |
| Interest Coverage | 2.34 |
Financial Efficiency
Return on equity (ROE) is 10.19% and return on invested capital (ROIC) is 1.99%.
| Return on Equity (ROE) | 10.19% |
| Return on Assets (ROA) | 1.44% |
| Return on Invested Capital (ROIC) | 1.99% |
| Return on Capital Employed (ROCE) | 3.02% |
| Revenue Per Employee | 379,911 |
| Profits Per Employee | 42,966 |
| Employee Count | 500 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 0.21 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +228.43% in the last 52 weeks. The beta is 0.06, so Pharma Mar's price volatility has been lower than the market average.
| Beta (5Y) | 0.06 |
| 52-Week Price Change | +228.43% |
| 50-Day Moving Average | 94.92 |
| 200-Day Moving Average | 70.86 |
| Relative Strength Index (RSI) | 18.37 |
| Average Volume (20 Days) | 51 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharma Mar had revenue of 189.96 million and earned 21.48 million in profits.
| Revenue | 189.96M |
| Gross Profit | 179.34M |
| Operating Income | 8.30M |
| Pretax Income | 11.73M |
| Net Income | 21.48M |
| EBITDA | 12.67M |
| EBIT | 8.30M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 152.23 million in cash and 56.14 million in debt, giving a net cash position of 96.09 million.
| Cash & Cash Equivalents | 152.23M |
| Total Debt | 56.14M |
| Net Cash | 96.09M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 213.44M |
| Book Value Per Share | n/a |
| Working Capital | 169.17M |
Cash Flow
In the last 12 months, operating cash flow was -10.33 million and capital expenditures -8.90 million, giving a free cash flow of -19.23 million.
| Operating Cash Flow | -10.33M |
| Capital Expenditures | -8.90M |
| Free Cash Flow | -19.23M |
| FCF Per Share | n/a |
Margins
Gross margin is 94.41%, with operating and profit margins of 4.37% and 11.31%.
| Gross Margin | 94.41% |
| Operating Margin | 4.37% |
| Pretax Margin | 6.17% |
| Profit Margin | 11.31% |
| EBITDA Margin | 6.67% |
| EBIT Margin | 4.37% |
| FCF Margin | n/a |
Dividends & Yields
Pharma Mar does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 57.46% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 1.50% |
| FCF Yield | -1.34% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharma Mar has an Altman Z-Score of 6.33.
| Altman Z-Score | 6.33 |
| Piotroski F-Score | n/a |